Patents by Inventor Michelle E. McClements

Michelle E. McClements has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gene therapy for retinal disease
    Patent number: 12649007
    Abstract: A method of treating a retinal disease in a subject in need thereof, the method comprising administering to the subject a vector that comprises a mirtron for knocking down expression of a target gene expressed in the retina and a gene therapy vector comprising a mirtron for rhodopsin knock-down.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: June 9, 2026
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Harry O. Orlans, Robert E. Maclaren, Michelle E. McClements, Alun R Barnard
  • Gene Therapy for Retinal Disease
    Publication number: 20240191257
    Abstract: The invention provides methods for treating, preventing or reversing retinal degeneration. The methods administering to the subject a vector that expresses a Cadherin-related family member 1 (CDHR1) polypeptide. The invention also provides gene therapy vectors that expresses a CDHR1 polypeptide, host cells that express the gene therapy vectors, and pharmaceutical compositions comprising the gene therapy vector.
    Type: Application
    Filed: March 30, 2022
    Publication date: June 13, 2024
    Inventors: Imran H. Yusuf, Robert E. MacLaren, Peter Charbel Issa, Michelle E. McClements
  • GENE THERAPY FOR RETINAL DISEASE
    Publication number: 20220249702
    Abstract: A method of treating a retinal disease in a subject in need thereof, the method comprising administering to the subject a vector that comprises a mirtron for knocking down expression of a target gene expressed in the retina and a gene therapy vector comprising a mirtron for rhodopsin knock-down.
    Type: Application
    Filed: October 25, 2019
    Publication date: August 11, 2022
    Inventors: Harry O. ORLANS, Robert E. MACLAREN, Michelle E. MCCLEMENTS, Alun R. BARNARD
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF STARGARDT DISEASE
    Publication number: 20210147870
    Abstract: The present disclosure provides an adeno-associated viral (AAV) vector system for expressing a human ABCA4 protein in a target cell, the AAV vector system comprising a first AAV vector comprising a first nucleic acid sequence and a second AAV vector comprising a second nucleic acid sequence; wherein the first nucleic acid sequence comprises a 5? end portion of an ABCA4 coding sequence (CDS) and the second nucleic acid sequence comprises a 3? end portion of an ABCA4 CDS, and the 5? end portion and the 3? end portion together encompass the entire ABCA4 CDS; wherein the first nucleic acid sequence comprises a sequence of contiguous nucleotides corresponding to nucleotides 105 to 3597 of SEQ ID NO: 1; wherein the second nucleic acid sequence comprises a sequence of contiguous nucleotides corresponding to nucleotides 3806 to 6926 of SEQ ID NO: 1; wherein the first nucleic acid sequence and the second nucleic acid sequence each comprise a region of sequence overlap with the other; and wherein the region of sequence
    Type: Application
    Filed: April 5, 2019
    Publication date: May 20, 2021
    Inventors: Gregory S. Robinson, Michelle E. McClements, Robert Maclaren